Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, India.
Department of Clinical Virology, Institute of Liver and Biliary Sciences, New Delhi, India.
Indian J Med Microbiol. 2023 Mar-Apr;42:46-48. doi: 10.1016/j.ijmmb.2023.01.010. Epub 2023 Feb 2.
COVID-19, the pandemic caused by the SARS-CoV-2, is a global health calamity and one of the greatest challenges faced by the humankind across the globe. The virus originated in Wuhan, China and spread rapidly to more than 200 countries/nations, affected more than 600 billion individuals and caused around 65 lakh deaths worldwide. Since the start of the pandemic, SARS-CoV-2 mutates and accumulates genetic variations which constantly resulted in the emergence of new variants.
The current article discusses about the new omicron sub variant BF.7, and how this BF.7 variant may pose risk in India, if it overrides the current COVID-19 circulating variants.
The emergence and potential consequences of the circulating SARS-CoV-2 variants usually augment virus transmissibility and host immune evasion. The current spurt in COVID-19 infections in China which has alarmed people around the world, is believed to be driven by an omicron sub variant BF.7. Although India has been reporting a "steady decline" in COVID-19 cases, we need constant surveillance to keep a track of the new emerging variants in circulation. Keeping in mind, the new surge in COVID-19 cases across many nations, we discuss about the new variant and its possible impact on India.
由 SARS-CoV-2 引起的 COVID-19 大流行是一场全球性的卫生灾难，也是全球人类面临的最大挑战之一。该病毒源自中国武汉，迅速传播到 200 多个国家/地区，影响了超过 6000 亿人，导致全球约 650 万人死亡。自大流行开始以来，SARS-CoV-2 不断发生变异并积累遗传变异，这不断导致新变体的出现。
本文讨论了新的 omicron 亚变体 BF.7，以及如果它超过当前流行的 COVID-19 变体，BF.7 变体在印度可能构成的风险。
循环的 SARS-CoV-2 变体的出现和潜在后果通常会增加病毒的传播能力和宿主免疫逃逸能力。目前中国 COVID-19 感染的激增令全球震惊，据信是由 omicron 亚变体 BF.7 驱动的。尽管印度报告的 COVID-19 病例一直在“稳步下降”，但我们需要进行持续监测，以跟踪流行中的新出现变体。考虑到许多国家 COVID-19 病例的新激增，我们讨论了新变体及其对印度的可能影响。
